

Personalised Cancer Medicine Flashcards 2021

Pancreatic Cancer



Standard

Germ-line BRCA 1-2
Microsatellite Instability*

Recommended

NTRK

Currently not recommended

ATM, PALB2, p53, KRAS, CDKN2,
SMAD4, MLL3, TGFBR2, ARID1A,
ALK, BRAF, HER2, ROS, RRG1

* By either IHC (MLH1, PMS2, MSH2 a MSH6) or by genomic study(BAT25 and BAT26, D2S123, D5S346 and D17S250).

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System
The **Recommended** category is based on current recommendations by EMEA and FDA

1. Curtin NJ, Drew Y, Sharma-Saha S. Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy. *Nat Rev Clin Oncol*. 2019 Dec;16(12):725-726. doi: 10.1038/s41571-019-0285-2.
2. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440.
3. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med*. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387.



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

